Chicago, IL, United States
Chicago, IL, United States

Time filter

Source Type

Albrecht J.,John Stroger Jr Hospital Of Cook County | Werth V.P.,Philadelphia Medical Center | Werth V.P.,University of Pennsylvania
Lupus | Year: 2010

Cutaneous lupus erythematosus (CLE) is a clinically heterogeneous group of rare skin diseases that only rarely have been subjected to controlled clinical trials. This may have been partly due to a lack of suitable validated outcome instruments. Recently, the Food and Drug Administration (FDA) mandated that organ-specific trials for lupus erythematosus need to use a combination of different outcome measures. The patients condition needs to be assessed in terms of quality of life, the patients global response, and organ-specific instruments that measure activity of the disease as well as damage due to the disease. For the skin, the only formally validated and published instrument is currently the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). This paper discusses the background of the development of the CLASI as well as issues related to its use and interpretation in the context of clinical research of CLE. © The Author(s), 2010.


Hamad H.,John Stroger Jr Hospital Of Cook County | Adab K.,John Stroger Jr Hospital Of Cook County | Shah M.,John Stroger Jr Hospital Of Cook County
International Journal of Clinical and Experimental Medicine | Year: 2016

Tyrosine kinase inhibitors (TKIs) are targeted molecular therapies widely used for different types of cancer. Their toxicity profile involves multiple organ systems, and the most common hematological toxicity is myelosuppression. Erythrocytosis is an uncommonly reported side effect of TKIs. We report here a case of erythrocytosis in response to the TKI Sunitinib in a patient with metastatic renal cell carcinoma that resolved with the discontinuation of the medication. The patient remained disease free with normal hemoglobin after three years of follow up. While the mechanism of this side effect remains anecdotal, our case reflects some of the different suggested mechanisms to explain it, including both erythropoietin (EPO) dependent and independent pathways. Further research aimed to reveal these pathways could lead to a general better understanding of the mechanisms governing red cell production and also can be used to gauge and monitor response to treatment with TKIs. © 2016, E-Century Publishing Corporation. All rights reserved.


PubMed | John Stroger Jr Hospital Of Cook County
Type: | Journal: International journal of pediatrics | Year: 2011

Despite significant progress in the treatment of preterm neonates, bronchopulmonary dysplasia (BPD) continues to be a major cause of neonatal morbidity. Affected infants suffered from long-term pulmonary and nonpulmonary sequel. The pulmonary sequels include reactive airway disease and asthma during childhood and adolescence. Nonpulmonary sequels include poor coordination and muscle tone, difficulty in walking, vision and hearing problems, delayed cognitive development, and poor academic achievement. As inflammation seems to be a primary mediator of injury in pathogenesis of BPD, role of steroids as antiinflammatory agent has been extensively studied and proven to be efficacious in management. However, evidence is insufficient to make a recommendation regarding other glucocorticoid doses and preparations. Numerous studies have been performed to investigate the effects of steroid. The purpose of this paper is to evaluate these studies in order to elucidate the beneficial and harmful effects of steroid on the prevention and treatment of BPD.


PubMed | John Stroger Jr Hospital Of Cook County
Type: Journal Article | Journal: Lupus | Year: 2010

Cutaneous lupus erythematosus (CLE) is a clinically heterogeneous group of rare skin diseases that only rarely have been subjected to controlled clinical trials. This may have been partly due to a lack of suitable validated outcome instruments. Recently, the Food and Drug Administration (FDA) mandated that organ-specific trials for lupus erythematosus need to use a combination of different outcome measures. The patients condition needs to be assessed in terms of quality of life, the patients global response, and organ-specific instruments that measure activity of the disease as well as damage due to the disease. For the skin, the only formally validated and published instrument is currently the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). This paper discusses the background of the development of the CLASI as well as issues related to its use and interpretation in the context of clinical research of CLE.

Loading John Stroger Jr Hospital Of Cook County collaborators
Loading John Stroger Jr Hospital Of Cook County collaborators